CY1109173T1 - Κρυσταλλικη μορφη του δις [(ε)-7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2-[μεθυλ(μεθυλσουλφονυλ)αμινο]πυριμιδιν-5-υλ](3r,5s)-3,5-διϋδροξυεπτ-6-ενοϊκο οξυ] αλατος ασβεστιου - Google Patents
Κρυσταλλικη μορφη του δις [(ε)-7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2-[μεθυλ(μεθυλσουλφονυλ)αμινο]πυριμιδιν-5-υλ](3r,5s)-3,5-διϋδροξυεπτ-6-ενοϊκο οξυ] αλατος ασβεστιουInfo
- Publication number
- CY1109173T1 CY1109173T1 CY20091100661T CY091100661T CY1109173T1 CY 1109173 T1 CY1109173 T1 CY 1109173T1 CY 20091100661 T CY20091100661 T CY 20091100661T CY 091100661 T CY091100661 T CY 091100661T CY 1109173 T1 CY1109173 T1 CY 1109173T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methylsulfonyl
- pyrimidin
- fluorophenyl
- isopropyl
- bis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Περιγράφονται δύο πολυμορφικές μορφές του δις[(Ε)-7-[4-(4-φθοροφαινυλ)6-ισοπροπυλ-2-[μεθυλ(μεθυλσουλφονυλ)αμινο]πυριμιδιν-5-υλ](3R,5S)-3,5-διϋδροξυεπτ-6-ενοϊκο οξυ] άλατος ασβεστίου, διεργασίες για την παρασκευή τους και η χρήση τους ως αναστολείς HMG Co-A ρεδουκτάσης.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0321127A GB0321127D0 (en) | 2003-09-10 | 2003-09-10 | Chemical compounds |
GB0404859A GB0404859D0 (en) | 2004-03-04 | 2004-03-04 | Chemical compound |
EP04768376A EP1663989B1 (en) | 2003-09-10 | 2004-09-08 | CRYSTALLINE FORM OF BIS (E)-7- 4-(4-FLUOROPHENYL)-6-IS OPROPYL-2- METHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL&r sqb;(3R,5S)-3,5-DIHYDROXYHEPT-6 -ENOICACID CALCIUM SALT |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109173T1 true CY1109173T1 (el) | 2014-07-02 |
Family
ID=34276833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100661T CY1109173T1 (el) | 2003-09-10 | 2009-06-24 | Κρυσταλλικη μορφη του δις [(ε)-7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2-[μεθυλ(μεθυλσουλφονυλ)αμινο]πυριμιδιν-5-υλ](3r,5s)-3,5-διϋδροξυεπτ-6-ενοϊκο οξυ] αλατος ασβεστιου |
Country Status (32)
Country | Link |
---|---|
US (4) | US20060293355A1 (el) |
EP (1) | EP1663989B1 (el) |
JP (1) | JP2007505090A (el) |
KR (1) | KR20070019943A (el) |
CN (1) | CN1878760B (el) |
AR (1) | AR045628A1 (el) |
AT (1) | ATE428701T1 (el) |
AU (1) | AU2004270467B8 (el) |
BR (1) | BRPI0414236A (el) |
CA (1) | CA2537962C (el) |
CO (1) | CO5670355A2 (el) |
CY (1) | CY1109173T1 (el) |
DE (1) | DE602004020640D1 (el) |
DK (1) | DK1663989T3 (el) |
ES (1) | ES2324042T3 (el) |
HK (1) | HK1090361A1 (el) |
HR (1) | HRP20090335T1 (el) |
IL (1) | IL174073A (el) |
IS (1) | IS2689B (el) |
MX (1) | MXPA06002761A (el) |
MY (1) | MY142615A (el) |
NO (1) | NO336358B1 (el) |
NZ (1) | NZ545785A (el) |
PL (1) | PL1663989T3 (el) |
PT (1) | PT1663989E (el) |
RU (1) | RU2363697C2 (el) |
SA (1) | SA04250297B1 (el) |
SI (1) | SI1663989T1 (el) |
TW (1) | TWI370817B (el) |
UA (1) | UA85062C2 (el) |
UY (1) | UY28501A1 (el) |
WO (1) | WO2005023779A1 (el) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
GB0011120D0 (en) | 2000-05-09 | 2000-06-28 | Avecia Ltd | Process |
NL1015744C2 (nl) * | 2000-07-19 | 2002-01-22 | Dsm Nv | Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten. |
DK1417180T3 (da) * | 2001-07-13 | 2007-04-10 | Astrazeneca Uk Ltd | Fremstilling af aminopyrimidinforbindelser |
EP1323717A1 (en) | 2001-12-27 | 2003-07-02 | Dsm N.V. | Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives |
EP1375493A1 (en) | 2002-06-17 | 2004-01-02 | Dsm N.V. | Process for the preparation of an dioxane acetic acid ester |
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
CA2509344C (en) | 2002-12-16 | 2011-10-04 | Astrazeneca Uk Limited | Process for the preparation of pyrimidine compounds |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
GB0324791D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
GB0428328D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
GB0514078D0 (en) * | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
EP1948618A1 (en) * | 2006-09-18 | 2008-07-30 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin calcium |
TW200831469A (en) * | 2006-12-01 | 2008-08-01 | Astrazeneca Uk Ltd | Chemical process |
WO2010081861A1 (en) * | 2009-01-14 | 2010-07-22 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of rosuvastatin |
CN102317267A (zh) * | 2009-01-15 | 2012-01-11 | 埃吉斯药物股份公开有限公司 | 制备罗苏伐他汀盐的方法 |
HUP0900285A2 (en) | 2009-05-07 | 2011-01-28 | Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag | Rosuvastatin salts and preparation thereof |
WO2011074016A1 (en) | 2009-12-17 | 2011-06-23 | Matrix Laboratories Ltd | Novel polymorphic forms of rosuvastatin calcium and process for preparation of the same |
HU230737B1 (hu) | 2010-11-16 | 2018-01-29 | EGIS Gyógyszergyár Nyrt | Eljárás rosuvastatin só előállítására |
DE202011110043U1 (de) | 2010-11-22 | 2012-10-30 | Basf Se | Mehrkomponentensystem von Rosuvastatin-Calciumsalz und Sorbit |
WO2012143308A1 (en) | 2011-04-18 | 2012-10-26 | Basf Se | Multicomponent crystalline system of rosuvastatin calcium salt and vanillin |
WO2014050874A1 (ja) * | 2012-09-27 | 2014-04-03 | 東和薬品株式会社 | ロスバスタチンカルシウムの新規結晶形態およびその製造方法 |
RO129060B1 (ro) | 2013-04-25 | 2014-11-28 | Antibiotice S.A. | Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă |
EP3103878A4 (en) | 2014-02-06 | 2017-08-16 | API Corporation | Rosuvastatin calcium and process for producing intermediate thereof |
US10626093B2 (en) | 2016-04-18 | 2020-04-21 | Morepen Loboratories Limited | Polymorphic form of crystalline rosuvastatin calcium and novel processes for crystalline as well as amorphous rosuvastatin calcium |
CN105837516B (zh) * | 2016-05-16 | 2018-07-10 | 山东新时代药业有限公司 | 一种瑞舒伐他汀钙晶型及其制备方法 |
CN111050973B (zh) | 2017-09-13 | 2021-11-30 | 杰富意钢铁株式会社 | 金属板的双面摩擦搅拌接合方法及双面摩擦搅拌接合装置 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4645858A (en) * | 1982-03-22 | 1987-02-24 | G. D. Searle & Co. | Pentanedioic acid derivatives |
DE3741509A1 (de) * | 1987-12-08 | 1989-06-22 | Hoechst Ag | Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte |
KR900701778A (ko) | 1988-10-06 | 1990-12-04 | 예안 크라머, 한스 루돌프 하우스 | 피리미디닐- 치환된 하이드록시산, 락톤 및 에스테르, 및 이를 함유하는 약학적 조성물 |
US5026698A (en) * | 1988-11-02 | 1991-06-25 | Nissan Chemical Industries, Ltd. | Thienopyridine type mevalonolactones |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
US5278313A (en) * | 1992-03-27 | 1994-01-11 | E. R. Squibb & Sons, Inc. | Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors |
EP0577040B1 (de) * | 1992-07-02 | 1997-09-24 | Hoechst Aktiengesellschaft | Verfahren zur Herstellung von (3R,5S)6-Hydroxy-3,5-0-isopropyliden-3,5-dihydroxy-hexansäure-tert.-butylester |
PT1148049E (pt) | 1995-07-17 | 2005-02-28 | Warner Lambert Co | Formas cristalinas de hemi-sal de calcio do acido [r-(r*,r*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil)-1h-pirrole-1-heptanoico (atorvastatina) |
US6278001B1 (en) * | 1995-11-28 | 2001-08-21 | L'oréal | Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping |
FR2741620B1 (fr) | 1995-11-28 | 1997-12-26 | Oreal | Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline |
DE69719755T2 (de) | 1996-06-24 | 2003-11-20 | Novartis Ag | Polymorphe verbindungen |
SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
EP1055671B1 (en) * | 1998-12-10 | 2004-12-01 | Kaneka Corporation | A process for producing a simvastatin precursor |
GB9900339D0 (en) * | 1999-01-09 | 1999-02-24 | Zeneca Ltd | Chemical compounds |
GB9903472D0 (en) | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
WO2001022962A1 (en) | 1999-09-30 | 2001-04-05 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
ATE478665T1 (de) | 1999-11-17 | 2010-09-15 | Teva Pharma | Verfahren zur herstellung einer polymorphen form von atorvastatin calcium |
GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
AU2000254249A1 (en) | 2000-03-28 | 2001-10-08 | Biocon India Limited | Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1- |
GB0011120D0 (en) * | 2000-05-09 | 2000-06-28 | Avecia Ltd | Process |
GB0011163D0 (en) | 2000-05-10 | 2000-06-28 | Astrazeneca Ab | Chemical compound |
NL1015744C2 (nl) * | 2000-07-19 | 2002-01-22 | Dsm Nv | Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten. |
SK5232003A3 (en) | 2000-10-05 | 2004-06-08 | Biogal Gyogyszergyar | Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
IL155890A0 (en) | 2000-11-16 | 2003-12-23 | Teva Pharma | HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE |
US6777552B2 (en) * | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
NL1017548C2 (nl) | 2001-03-09 | 2002-09-10 | Synthon Bv | Een lactonisatie proces. |
IN190564B (el) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
ES2214169T1 (es) * | 2001-06-06 | 2004-09-16 | Bristol-Myers Squibb Company | Procedimiento de preparacion de sulfonas quirales dioles e inhibidores del dihidroxiacido hmg coa reductasa. |
DK1417180T3 (da) * | 2001-07-13 | 2007-04-10 | Astrazeneca Uk Ltd | Fremstilling af aminopyrimidinforbindelser |
PL370407A1 (en) | 2001-08-16 | 2005-05-30 | Teva Pharmaceutical Industries Ltd. | Processes for preparing calcium salt forms of statins |
EP1423365A1 (en) | 2001-08-22 | 2004-06-02 | Ciba Specialty Chemicals Holding Inc. | Process for the preparation of indole derivatives |
US7407772B2 (en) | 2001-09-24 | 2008-08-05 | Merck & Co., Inc. | Screening and selection methods for statin drug combinations |
AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
EP1323717A1 (en) | 2001-12-27 | 2003-07-02 | Dsm N.V. | Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives |
KR100511533B1 (ko) | 2002-04-09 | 2005-08-31 | 임광민 | 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법 |
AR039836A1 (es) | 2002-05-21 | 2005-03-02 | Ranbaxy Lab Ltd | Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina |
EP1375493A1 (en) | 2002-06-17 | 2004-01-02 | Dsm N.V. | Process for the preparation of an dioxane acetic acid ester |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
CA2509344C (en) | 2002-12-16 | 2011-10-04 | Astrazeneca Uk Limited | Process for the preparation of pyrimidine compounds |
GB0312896D0 (en) * | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
UY28501A1 (es) * | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
GB0321827D0 (en) * | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
GB0324791D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
DE10352659B4 (de) | 2003-11-11 | 2007-09-13 | Ratiopharm Gmbh | Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren |
WO2005054207A1 (en) * | 2003-12-04 | 2005-06-16 | Glenmark Pharmaceuticals Limited | Process for the preparation of pyrimidine derivatives |
US7241800B2 (en) * | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
US7161004B2 (en) * | 2004-06-21 | 2007-01-09 | Dr. Reddy's Laboratories Limited | Processes to produce intermediates for rosuvastatin |
WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
GB0428328D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
BRPI0611707A2 (pt) | 2005-06-29 | 2012-04-24 | Compumedics Ltd | conjunto de sensor com ponte condutiva |
TW200831469A (en) * | 2006-12-01 | 2008-08-01 | Astrazeneca Uk Ltd | Chemical process |
-
2004
- 2004-09-07 UY UY28501A patent/UY28501A1/es not_active Application Discontinuation
- 2004-09-08 WO PCT/GB2004/003829 patent/WO2005023779A1/en active Application Filing
- 2004-09-08 BR BRPI0414236-5A patent/BRPI0414236A/pt not_active Application Discontinuation
- 2004-09-08 PT PT04768376T patent/PT1663989E/pt unknown
- 2004-09-08 EP EP04768376A patent/EP1663989B1/en active Active
- 2004-09-08 KR KR1020067004952A patent/KR20070019943A/ko not_active Application Discontinuation
- 2004-09-08 AT AT04768376T patent/ATE428701T1/de active
- 2004-09-08 SI SI200431145T patent/SI1663989T1/sl unknown
- 2004-09-08 NZ NZ545785A patent/NZ545785A/en not_active IP Right Cessation
- 2004-09-08 ES ES04768376T patent/ES2324042T3/es active Active
- 2004-09-08 RU RU2006111354/04A patent/RU2363697C2/ru not_active IP Right Cessation
- 2004-09-08 MX MXPA06002761A patent/MXPA06002761A/es active IP Right Grant
- 2004-09-08 PL PL04768376T patent/PL1663989T3/pl unknown
- 2004-09-08 AU AU2004270467A patent/AU2004270467B8/en not_active Ceased
- 2004-09-08 DE DE602004020640T patent/DE602004020640D1/de active Active
- 2004-09-08 UA UAA200602622A patent/UA85062C2/uk unknown
- 2004-09-08 DK DK04768376T patent/DK1663989T3/da active
- 2004-09-08 CN CN2004800308267A patent/CN1878760B/zh active Active
- 2004-09-08 JP JP2006525882A patent/JP2007505090A/ja active Pending
- 2004-09-08 CA CA2537962A patent/CA2537962C/en active Active
- 2004-09-08 US US10/571,254 patent/US20060293355A1/en not_active Abandoned
- 2004-09-09 MY MYPI20043667A patent/MY142615A/en unknown
- 2004-09-10 TW TW093127580A patent/TWI370817B/zh not_active IP Right Cessation
- 2004-09-10 AR ARP040103249A patent/AR045628A1/es unknown
- 2004-09-18 SA SA04250297A patent/SA04250297B1/ar unknown
-
2006
- 2006-03-02 IL IL174073A patent/IL174073A/en active IP Right Grant
- 2006-03-14 NO NO20061181A patent/NO336358B1/no not_active IP Right Cessation
- 2006-03-15 CO CO06026185A patent/CO5670355A2/es not_active Application Discontinuation
- 2006-03-30 IS IS8385A patent/IS2689B/is unknown
- 2006-09-28 HK HK06110818A patent/HK1090361A1/xx unknown
-
2009
- 2009-06-10 HR HR20090335T patent/HRP20090335T1/xx unknown
- 2009-06-24 CY CY20091100661T patent/CY1109173T1/el unknown
- 2009-11-10 US US12/615,935 patent/US20100222373A1/en not_active Abandoned
-
2011
- 2011-03-01 US US13/038,245 patent/US8436167B2/en active Active
-
2013
- 2013-04-08 US US13/858,553 patent/US20130225622A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109173T1 (el) | Κρυσταλλικη μορφη του δις [(ε)-7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2-[μεθυλ(μεθυλσουλφονυλ)αμινο]πυριμιδιν-5-υλ](3r,5s)-3,5-διϋδροξυεπτ-6-ενοϊκο οξυ] αλατος ασβεστιου | |
IS8478A (is) | Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess | |
EE200200445A (et) | 7-[4-(4-fluorofenüül)-6-isopropüül-2-metüül(metüülsulfonüül)amino]pürimidiin-5-üül] -(3R,5S)-3,5- dihüdroksühept-6-enohappe kristalsed soolad | |
TWI341310B (en) | Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt | |
NO20013368L (no) | Krystallinsk bis((E)-7-(4-(4-fluorfenyl)-6-isopropyl-2- (metyl(metylsulfonyl)amino)pyrimidin-5-yl)(3R,5S)-3,5-dihydroksyhept-6-ensyre)kalsiumsalt | |
NO20061324L (no) | Polymorfe former av en kjent antihyperlinemisk forbindelse | |
WO2009157014A3 (en) | A process for preparing hmg-coa reductase inhibitors and intermediates | |
PL1704144T3 (pl) | Sposób wytwarzania soli wapniowej kwasu (E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo](3R,5S)-3,5-dihydroksy-6-heptenowego | |
UY30336A1 (es) | Composiciones farmacéuticas conteniendo ácido (e)-7-(4-(4-fluorofenil)-6-isopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il)-(3r,5s)-3,5-dihidroxihept-6-enoico y sales farmacéuticamente aceptables de la misma |